ARQT Q4 2025 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$130M+81.5% YoY

Gross Profit

$118M91.0% margin

Operating Income

$18M14.2% margin

Net Income

$17M13.4% margin

EPS (Diluted)

$0.13

QoQ Revenue Growth

+30.5%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$26M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$433M

Total Liabilities

$243M

Stockholders' Equity

$189M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$130M	$71M	+81.5%
Gross Profit	$118M	$64M	+82.8%
Operating Income	$18M	-$8M	+340.9%
Net Income	$17M	-$11M	+261.2%